Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/review2 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Cited By ~ 90

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v2/review3 ◽

2019 ◽

Author(s):

Bastiaan E de Galan

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12898 ◽

2017 ◽

Vol 19 (6) ◽

pp. 874-882 ◽

Cited By ~ 28

Author(s):

Takashi Kadowaki ◽

Nobuya Inagaki ◽

Kazuoki Kondo ◽

Kenichi Nishimura ◽

Genki Kaneko ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

Journal of Diabetes Investigation ◽

10.1111/j.2040-1124.2012.00226.x ◽

2012 ◽

Vol 3 (6) ◽

pp. 517-525 ◽

Cited By ~ 24

Author(s):

Yutaka Seino ◽

Shinzo Hiroi ◽

Masashi Hirayama ◽

Kohei Kaku

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Extension Study ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo

Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1359259 ◽

2017 ◽

Vol 18 (13) ◽

pp. 1291-1300 ◽

Cited By ~ 16

Author(s):

Takashi Kadowaki ◽

Kazuoki Kondo ◽

Noriyuki Sasaki ◽

Kyoko Miyayama ◽

Shoko Yokota ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo

Review for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v2/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Decision letter for "Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: a randomised, double‐blind, placebo‐controlled trial"

10.1111/dom.13909/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo